Alexandra Kadl

University of Virginia Health System — United States

Medicine · Health Sciences

34h-index6.2kcitations105works8.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Long-Term Effects of COVID-19(28), COVID-19 Clinical Research Studies(20), SARS-CoV-2 and COVID-19 Research(11), Intensive Care Unit Cognitive Disorders(11), Respiratory Support and Mechanisms(10)

Publications101 total

ACE-2-like enzymatic activity in COVID-19 convalescents with persistent pulmonary symptoms associated with immunoglobulin
mBio·2025Open Access
The Effect of Advanced Interventional Approaches on Patient Outcomes After Pulmonary Embolism
American Journal of Respiratory and Critical Care Medicine·2025
Distinct type 1 immune networks underlie the severity of restrictive lung disease after COVID-19
Nature Immunology·2025· 8 cited
ACE-2-like Enzymatic Activity in COVID-19 Convalescents with Persistent Pulmonary Symptoms Associated with Immunoglobulin
2025Open Access
Prevalence and associations of insomnia after COVID-19 infection
Journal of Clinical Sleep Medicine·2024· 3 citedOpen Access
An aberrant immune–epithelial progenitor niche drives viral lung sequelae
Nature·2024· 60 citedOpen Access
Mammalian Meat Allergy and IgE to Alpha-Gal in Central Virginia: Findings From a COVID-19 Vaccine and Patient Cohort
The Journal of Allergy and Clinical Immunology In Practice·2024· 5 cited
Proximal immune-epithelial progenitor interactions drive chronic tissue sequelae post-COVID-19
The Journal of Immunology·2024· 1 cited
A protective role for B-1 cells and oxidation-specific epitope IgM in lung fibrosis
2024· 1 citedOpen Access
Distinct Type 1 Immune Networks Underlie the Severity of Restrictive Lung Disease after COVID-19
2024· 1 citedOpen Access
ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients
mBio·2024· 8 citedOpen Access
Pulmonary Function and Survival 1 Year After Dupilumab Treatment of Acute Moderate to Severe Coronavirus Disease 2019: A Follow-up Study From a Phase 2a Trial
Open Forum Infectious Diseases·2024· 4 citedOpen Access
Proximal immune-epithelial progenitor interactions drive chronic tissue sequelae post COVID-19
2023· 1 citedOpen Access
Plasma oxidized phospholipidome as an indicator of comorbidities in critically ill patients
Free Radical Biology and Medicine·2023
Proximal immune-epithelial progenitor interactions drive chronic tissue sequelae post COVID-19
2023· 6 citedOpen Access
Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial
2023· 3 citedOpen Access
Longitudinal impact of COVID‐19 on lung function in lung transplant recipients: Time to stop worrying?
Transplant Infectious Disease·2023· 1 citedOpen Access
Author response for "Chronic Neurocognitive, Neuropsychological, and Pulmonary Symptoms in Outpatient and Inpatient Cohorts After COVID-19 Infection"
2023
Dysregulated immune networks define distinct respiratory phenotypes of post-acute sequelae of COVID-19
The Journal of Immunology·2023Open Access
Supplementary Tables S1 & S2 from Sustained Expression of Early Growth Response Protein-1 Blocks Angiogenesis and Tumor Growth
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Norbert Leitinger(23), Bernd R. Binder(11), Флориан Грубер(10), Judith A. Woodfolk(8), Valery N. Bochkov(7), Kyle B. Enfield(7), Lyndsey M. Muehling(6), Glenda Canderan(6), Jeffrey M. Sturek(6), Joakim Huber(5), Gerhard Krönke(5), Jeffrey M. Wilson(5), Chintan Ramani(5), Poonam Sharma(4), Martin Bilban(4), Alexander Fürnkranz(4), Thurl E. Harris(4), Kodi S. Ravichandran(3), Akshaya K. Meher(3), Wenshu Chen(3)